Hemab Therapeutics (COAG) vs Taysha Gene Therapies (TSHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Taysha Gene Therapies is the larger company by market cap ($1.44 billion vs $1.44 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COAG | TSHA |
|---|---|---|
| Share price | $30.89 | $4.43 |
| Market cap | $1.44B | $1.44B |
| 1-day change | +7.63% | 0.00% |
| YTD return | — | -19.45% |
| 1-year return | — | -12.45% |
| 5-year return | — | -75.22% |
| EPS (TTM) | $-4.33 | $-0.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $55.42 | $7.30 |
| 52-week low | $23.00 | $3.69 |
| Distance from 52-week high | -44.26% | -39.32% |
| Analyst consensus | none | none |
| Avg. price target upside | +98.12% | +193.45% |
| Average volume | 458.71K | 3.28M |
| Shares outstanding | 46.71M | 325.83M |
| Employees | 59 | 99 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Hemab Therapeutics in Health Care and Taysha Gene Therapies in Healthcare.
About Hemab Therapeutics
COAG stock →Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 59 employees
About Taysha Gene Therapies
TSHA stock →Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.
Healthcare · Biotechnology · 99 employees
COAG vs TSHA FAQ
Which is bigger, Hemab Therapeutics or Taysha Gene Therapies?
Taysha Gene Therapies (TSHA) is larger, with a market capitalization of $1.44B compared with $1.44B for Hemab Therapeutics (COAG).
Are Hemab Therapeutics and Taysha Gene Therapies in the same industry?
No. Hemab Therapeutics is in the Health Care sector, while Taysha Gene Therapies is in Healthcare.